Lupin Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

The company?s product is a bioequivalent version of Farxiga and will be marketed for indications as per the approved labeling.

Dapagliflozin is indicated for the treatment of conditions including Type 2 Diabetes and certain cardiovascular and renal disorders.

The launch marks Lupin?s continued expansion in the US generics market and strengthens its presence in the oral anti-diabetic segment.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.

Shares of Lupin shed 0.88% to currently trade at Rs 2,312.10 on the BSE.

The approval covers multiple strengths, including 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg, as per the company?s regulatory filing dated April 8.

The company has also received tentative approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets (2.5 mg/1,000 mg). The approved product is bioequivalent to Xigduo XR and will be used for the same indications as per the approved label.

Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients.

The pharmaceutical company reported a 37.46% surge in consolidated net profit to Rs 1,175.55 crore in Q3 FY26 as against Rs 855.16 crore posted in Q3 FY25. Total revenue from operations jumped 24.26% year-on-year to Rs 7,167.52 crore in the quarter ended 31 December 2025.

Shares of Lupin shed 0.35% to Rs 2,285.60 on the BSE.

Lupin has granted 6,495 stock options under ESOP on 09 April 2026.

Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg. The company also received tentative approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 2.5 mg/1,000 mg.

The U.S. FDA has approved Lupin's Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets as bioequivalent to Xigduo? XR for the indications in the approved labeling.